Thymosin Alpha-1 for Hepatitis B in Japanese Patients: Randomized Trial Shows Safety and Response

Thymosin alpha-1 demonstrated safety and virological response in Japanese chronic hepatitis B patients in a randomized clinical trial, validating its efficacy in an Asian population.

Iino, S et al.·Journal of viral hepatitis·2005·Strong EvidenceRCT
RPEP-01050RCTStrong Evidence2005RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
RCT
Evidence
Strong Evidence
Sample
Not reported

What This Study Found

Thymosin alpha-1 showed safety and efficacy (HBeAg seroconversion, HBV DNA reduction) in Japanese chronic hepatitis B patients in a randomized controlled trial, validating immunotherapy-based HBV treatment in the high-prevalence Asian population.

Key Numbers

How They Did This

RCT study on thymosin-alpha-1, infection.

Why This Research Matters

Relevant for thymosin-alpha-1, infection, immune-function, clinical-trials.

The Bigger Picture

Advances peptide research with clinical implications.

What This Study Doesn't Tell Us

See abstract.

Questions This Raises

  • ?Further research needed.
  • ?Clinical translation to evaluate.

Trust & Context

Key Stat:
Key finding Thymosin alpha-1 showed safety and efficacy (HBeAg seroconversion, HBV DNA reduction) in Japanese chronic hepatitis B patients in a randomized control
Evidence Grade:
strong evidence.
Study Age:
Published in 2005.
Original Title:
The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trial.
Published In:
Journal of viral hepatitis, 12(3), 300-6 (2005)
Database ID:
RPEP-01050

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What was studied?

Thymosin Alpha-1 for Hepatitis B in Japanese Patients: Randomized Trial Shows Safety and Response

What was found?

Thymosin alpha-1 demonstrated safety and virological response in Japanese chronic hepatitis B patients in a randomized clinical trial, validating its efficacy in an Asian population.

Read More on RethinkPeptides

Cite This Study

RPEP-01050·https://rethinkpeptides.com/research/RPEP-01050

APA

Iino, S; Toyota, J; Kumada, H; Kiyosawa, K; Kakumu, S; Sata, M; Suzuki, H; Martins, E B. (2005). The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trial.. Journal of viral hepatitis, 12(3), 300-6.

MLA

Iino, S, et al. "The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trial.." Journal of viral hepatitis, 2005.

RethinkPeptides

RethinkPeptides Research Database. "The efficacy and safety of thymosin alpha-1 in Japanese pati..." RPEP-01050. Retrieved from https://rethinkpeptides.com/research/iino-2005-the-efficacy-and-safety

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.